Tolerance to factor VIII in a transgenic mouse expressing human factor VIII cDNA carrying an Arg593 to Cys substitution

Thrombosis and Haemostasis

Volumn 95, Issue 2, 2006, Pages 341-347

  Bril, Wendy S ^a   van Helden, Pauline M W ^a   Hausl, Christina ^b   Zuurveld, Marleen G ^a   Ahmad, Rafi U ^c   Hollestelle, Martine J ^a   Reitsma, Pieter H ^d   Fijnvandraat, Karin ^a   van Lier, Rene A W ^d   Schwarz, Hans Peter ^c   Mertens, Koen ^a,e   Reipert, Birgit M ^b,c   Voorberg, Jan ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b BMT Research   (Austria)

^c BAXTER BIOSCIENCE   (Austria)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Factor VIII; Haemophilia A B; Transgenic animals

Indexed keywords

ALBUMIN; ARGININE; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; COMPLEMENTARY DNA; CYSTEINE; GAMMA INTERFERON; INTERLEUKIN 10;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ARTICLE; BONE MARROW; CONTROLLED STUDY; FEMALE; HEMOPHILIA A; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; LIVER; MALE; MEMORY CELL; MOUSE; NONHUMAN; NONVIRAL GENE THERAPY; OOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; TISSUE DISTRIBUTION; TRANSGENIC MOUSE;

AMINO ACID SUBSTITUTION; ANIMALS; ARGININE; CYSTEINE; DNA, COMPLEMENTARY; FACTOR VIII; HUMANS; IMMUNE TOLERANCE; ISOANTIBODIES; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MODELS, ANIMAL;

EID: 33645554094     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH05-08-0559     Document Type: Article

References (40)

1. Hoyer LW. Hemophilia A. N Engl J Med 1994; 330: 38-47.
2. Mannucci PM, Tuddenham EG. The hemophilias - from royal genes to gene therapy. N Engl J Med 2001; 344: 1773-9.
3. Lollar P. Pathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX. J Thromb Haemost 2004; 2: 1082-95.
4. Bi L, Lawler AM, Antonarakis SE et al. Targeted disruption of the mouse factor VIII gene produces a model of hemophilia A. Nat Genet 1995; 10: 119-21.
5. Bi L, Sarkar R, Naas T et al. Further characterization of factor VIII-deficient mice created by gene targeting: RNA and protein studies. Blood 1996; 88: 3446-50.
6. Muchitsch EM, Turecek PL, Zimmermann K et al. Phenotypic expression of murine hemophilia. Thromb Haemost 1999; 82: 1371-3.
7. Qian J, Borovok M, Bi L et al. Inhibitor antibody development and T cell response to human factor VIII in murine hemophilia A. Thromb Haemost 1999; 81: 240-4.
8. Reipert BM, Ahmad RU, Turecek PL et al. Characterization of antibodies induced by human factor VIII in a murine knockout model of hemophilia A. Thromb Haemost 2000; 84: 826-32.
9. Sasgary M, Ahmad RU, Schwarz HP et al. Single cell analysis of factor VIII-specific T cells in hemophilic mice after treatment with human factor VIII. Thromb Haemost 2002; 87: 266-72.
10. Hausl C, Maier E, Schwarz HP et al. Long-term persistence of anti-factor VIII antibody-secreting cells in hemophilic mice after treatment with human factor VIII. Thromb Haemost 2002; 87: 840-5.
11. Hausl C, Ahmad RU, Schwarz HP et al. Preventing restimulation of memory B cells in hemophilia A: a potential new strategy for the treatment of antibody-dependent immune disorders. Blood 2004: 104, 115-22.
12. Qian J, Collins M, Sharpe AH et al. Prevention and treatment of factor VIII inhibitors in murine hemophilia A. Blood 2000; 95: 1324-9.
13. Rossi G, Sarkar J, Scandella D. Long-term induction of immune tolerance after blockade of CD40-CD40L interaction in a mouse model of hemophilia A. Blood 2001; 97: 2750-7.
14. Reipert BM, Sasgary M, Ahmad RU et al. Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce long lasting immune tolerance. Thromb Haemost 2001; 86: 1345-52.
15. Qian J, Burkly LC, Smith EP et al. Role of CD154 in the secondary immune response: the reduction of pre-existing splenic germinal centers and anti-factor VIII inhibitor titre. Eur J Immunol 2000: 30: 2548-54.
16. Lei TC and Scott DW. Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins. Blood 2005: 105: 4865-70.
17. Bril WS, MacLean PE, Kaijen PH et al. HLA class II genotype and factor VIII inhibitors in mild hemophilia A patients with an Arg593 to Cys mutation. Hemophilia 2004; 10: 509-14.
18. 593→Cys is related to antibody formation in a patient with mild hemophilia A. Blood 1997; 89: 4371-7.
19. 593→Cys mutation. Blood 1997; 90: 1902-10.
20. 618→Ser explains cross-reacting material-reduced hemophilia A. Br J Haematol 2000; 108: 241-6.
21. Needham M, Gooding C, Hudson K et al. LCR/MEL: a versatile system for high-level expression of heterologous proteins in erythroid cells. Nucleic Acids Res 1992; 20: 997-1003.
22. Pinkert CA, Ornitz DM, Brinster RL et al. An albumin enhancer located 10 kb upstream functions along with its promoter to direct efficient, liver-specific expression in transgenic mice. Genes Dev 1987; 1: 268-76.
23. Wagenaar GT, van Vuuren AJ, Girma M et al. Characterization of transgenic mice that secrete functional human protein C inhibitor into the circulation. Thromb Haemost 2000; 83: 93-101.
24. Hollestelle MJ, Thinnes T, Crain K et al. Tissue distribution of factor VIII gene expression in vivo - a closer look. Thromb Haemost 2001; 86: 855-61.
25. Leyte A, Mertens K, Distel B et al. Inhibition of human coagulation factor VIII by monoclonal antibodies. Mapping of functional epitopes with the use of recombinant factor VIII fragments. Biochem J 1989; 263: 187-94.
26. Lenting PJ, Donath MJ, van Mourik JA et al. Identification of a binding site for blood coagulation factor IXa on the light chain of human factor VIII. J Biol Chem 1994; 269: 7150-5.
27. Kasper CK, Aledort LM, Counts RB et al. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 869-72.
28. Billiau A and Matthys P. Modes of action of Freund's adjuvants in experimental models of autoimmune diseases. J Leukoc Biol 2001; 70: 849-60.
29. Evans GL, Morgan RA. Genetic induction of immune tolerance to human clotting factor VIII in a mouse model for hemophilia A. Proc Natl Acad Sci U S A 1998; 95: 5734-9.
30. Vigouroux S, Yvon E, Biagi E et al. Antigen-induced regulatory T cells. Blood 2004; 104: 26-33.
31. Jin DY, Zhang TP, Gui T et al. Creation of a mouse expressing defective human factor IX. Blood 2004; 104: 1733-9.
32. Sabatino DE, Armstrong E, Edmonson S et al. Novel hemophilia B mouse models exhibiting a range of mutations in the Factor IX gene. Blood 2004; 104: 2767-2774.
33. 593→Cys substitution. Thromb Haemost 1999; 81: 723-6.
34. Rawle FE, Shi CX, Brown B et al. Heterogeneity of the immune response to adenovirus-mediated factor VIII gene therapy in different inbred hemophilic mouse strains. J Gene Med 2004; 6: 1358-68.
35. Hay CR, Ollier W, Pepper L et al. HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. UKHCDO Inhibitor Working Party. Thromb Haemost 1997; 77: 234-7.
36. Oldenburg J, Picard JK, Schwaab R et al. HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII. Thromb Haemost 1997; 77: 238-42.
37. Jacquemin M, Vantomme V, Buhot C et al. CD4+ T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A. Blood 2003; 101: 1351-8.
38. Cook DN, Pisetsky DS, Schwartz DA. Toll-like receptors in the pathogenesis of human disease. Nat Immunol 2004; 5: 975-9.
39. Pipe SW, Saint-Remy JM, Walsh CE. New high technology products for the treatment of hemophilia. Hemophilia 2004; 10: 55-63.
40. Hough C, Lillicrap D. Gene therapy for hemophilia: an imperative to succeed. J Thromb Haemost 2005; 3: 1195-205.